Findings of this cohort study suggest that individualized ROIs carried an advantage over group-level ROIs for assessing longitudinal tau changes and may increase the sensitivity to detect treatment effects in AD clinical trials using longitudinal tau-PET as an outcome. The gene discussed is MAPT; the disease is Alzheimer disease.